Intellia Therapeutics, Inc.·4

Oct 3, 5:13 PM ET

Schultes Birgit C 4

4 · Intellia Therapeutics, Inc. · Filed Oct 3, 2025

Insider Transaction Report

Form 4
Period: 2025-10-01
Schultes Birgit C
EVP, Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2025-10-01$17.38/sh31$539105,184 total
Footnotes (1)
  • [F1]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person.

Documents

2 files